Hemogenyx Pharmaceuticals (HEMO) Competitors GBX 179.36 +1.36 (+0.76%) As of 07/25/2025 12:31 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock HEMO vs. OKYO, AREC, SAR, AOR, POLB, RLM, NSCI, OPTI, IXI, and OBDShould you be buying Hemogenyx Pharmaceuticals stock or one of its competitors? The main competitors of Hemogenyx Pharmaceuticals include OKYO Pharma (OKYO), Arecor Therapeutics (AREC), Sareum (SAR), AorTech International (AOR), Poolbeg Pharma (POLB), Realm Therapeutics (RLM), NetScientific (NSCI), OptiBiotix Health (OPTI), IXICO (IXI), and Oxford BioDynamics (OBD). These companies are all part of the "biotechnology" industry. Hemogenyx Pharmaceuticals vs. Its Competitors OKYO Pharma Arecor Therapeutics Sareum AorTech International Poolbeg Pharma Realm Therapeutics NetScientific OptiBiotix Health IXICO Oxford BioDynamics Hemogenyx Pharmaceuticals (LON:HEMO) and OKYO Pharma (LON:OKYO) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, dividends, earnings and analyst recommendations. Which has more risk and volatility, HEMO or OKYO? Hemogenyx Pharmaceuticals has a beta of 3.14, suggesting that its share price is 214% more volatile than the S&P 500. Comparatively, OKYO Pharma has a beta of -0.06, suggesting that its share price is 106% less volatile than the S&P 500. Does the media prefer HEMO or OKYO? In the previous week, Hemogenyx Pharmaceuticals' average media sentiment score of 0.00 equaled OKYO Pharma'saverage media sentiment score. Company Overall Sentiment Hemogenyx Pharmaceuticals Neutral OKYO Pharma Neutral Which has stronger valuation & earnings, HEMO or OKYO? Hemogenyx Pharmaceuticals is trading at a lower price-to-earnings ratio than OKYO Pharma, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioHemogenyx PharmaceuticalsN/AN/A-£6.89K-£0.20-917.53OKYO PharmaN/AN/A-£6.70M-£0.01N/A Is HEMO or OKYO more profitable? Hemogenyx Pharmaceuticals' return on equity of -80.66% beat OKYO Pharma's return on equity.Company Net Margins Return on Equity Return on Assets Hemogenyx PharmaceuticalsN/A -80.66% -37.79% OKYO Pharma N/A -397.13%-154.72% Do institutionals and insiders have more ownership in HEMO or OKYO? 0.8% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 10.7% of Hemogenyx Pharmaceuticals shares are held by company insiders. Comparatively, 31.9% of OKYO Pharma shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. SummaryHemogenyx Pharmaceuticals beats OKYO Pharma on 5 of the 8 factors compared between the two stocks. Get Hemogenyx Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for HEMO and its competitors with MarketBeat's FREE daily newsletter. Email Address Media Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart HEMO vs. The Competition Export to ExcelMetricHemogenyx PharmaceuticalsBiotechnology IndustryMedical SectorLON ExchangeMarket Cap£6.39M£137.04M£5.74B£3.02BDividend YieldN/A3.74%4.70%5.02%P/E Ratio-917.533.7521.93160.65Price / SalesN/A4,478.16461.46278,114.27Price / Cash2.0513.1925.1827.97Price / Book728.0542.328.624.70Net Income-£6.89K-£90.99M£3.25B£5.90B7 Day Performance38.53%4.92%4.31%0.40%1 Month Performance19.38%9.07%11.60%7.19%1 Year Performance12,992.04%193.33%35.38%70.37% Hemogenyx Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)HEMOHemogenyx PharmaceuticalsN/AGBX 179.36+0.8%N/A+12,992.0%£6.39MN/A-917.5314Gap UpOKYOOKYO PharmaN/AN/AN/AN/A£23.24MN/A-140.007Gap DownARECArecor TherapeuticsN/AGBX 56.79+2.3%N/A-40.1%£21.44M£6.04M-2.0110News CoverageGap DownSARSareumN/AGBX 17.10-9.5%N/A-40.4%£21.36MN/A-4.053,211Gap DownAORAorTech InternationalN/AN/AN/AN/A£19.99M£539K-33.383POLBPoolbeg PharmaN/AGBX 2.92+2.5%N/A-76.7%£15.01MN/A0.0012Gap DownHigh Trading VolumeRLMRealm TherapeuticsN/AN/AN/AN/A£13.41M£501.92K-0.66N/ANSCINetScientificN/AN/AN/AN/A£12.81M£1.45M-486.3626OPTIOptiBiotix HealthN/AGBX 11.40+1.3%N/A-64.6%£11.17M£590.01K-3.611Gap DownIXIIXICON/AGBX 11.23-2.4%N/A+60.4%£10.40M£11.50M-2.9189Gap UpOBDOxford BioDynamicsN/AGBX 0.52+1.0%N/A-93.6%£9.80M£5.75M-0.0945 Related Companies and Tools Related Companies OKYO Pharma Alternatives Arecor Therapeutics Alternatives Sareum Alternatives AorTech International Alternatives Poolbeg Pharma Alternatives Realm Therapeutics Alternatives NetScientific Alternatives OptiBiotix Health Alternatives IXICO Alternatives Oxford BioDynamics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:HEMO) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredTurn $1K into $50K with This DeFi GemI've never been more confident about a DeFi opportunity. This isn't about complex trading or risky bets. Th...Crypto 101 Media | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Hemogenyx Pharmaceuticals Plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Hemogenyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free HEMO Stock Alerts